Beijing Lepu Medical Technology Co., Ltd. is a wholly owned subsidiary of the listed company Lepu (Beijing) Medical Devices Co., Ltd. (sz.300003), with a registered capital of 30 million yuan, is a multi-faceted development of collective external diagnostic reagents and related equipment research and development, production and sales in one of the enterprises.
As a wholly-owned subsidiary of LPMC, LPMC's in vitro diagnostic products have enriched the group's product line, which is mainly composed of instruments and consumables, and helped LPMC become the largest and most professional cardiovascular medical industry chain group in China.
Leopold's products include three categories: cardiac marker POCT bedside diagnostic series, CFMS Siffith coagulation test series and molecular diagnostic series of cardiovascular diseases under research. We have successfully established various professional technology platforms such as nanoimmunity, fluorescence detection, microfluidics, chemiluminescence and monoclonal antibody preparation. The company adopts advanced technology, developed a new generation of POCT immunoquantitative analyzer and supporting reagents, widely praised by the domestic market, and exported to Europe, Asia, Latin America and other countries, the company is the first domestic independent development of coagulation - fibrinolysis analysis of the whole picture of the enterprise, the CFMS Sifens thromboelastography and related reagents is called the coagulation test of the national brand of the work, and broke the monopoly of the European and American products. It breaks the monopoly of European and American products and fills the blank in China; and the molecular diagnostic technology makes LPKF walk in the forefront of the high-end market in the field of testing.
With the efforts of a dynamic team*** and relying on the rich resources of the Group in the field of cardiovascular healthcare, LP Technology will strive to become a first-class cardiovascular disease diagnostic expert in China.